Discover Great Companies Discover Great Clients
Companies Salaries Jobs
Jobs |
Jobs Companies Salary Majors

Company Overview

Development Stage

  • Stage: 天使+。

About the Company

[Summary] 大数据驱动靶向药物及精准医疗决策工具研发

英诺迈博生物医药科技(上海)有限公司成立于2021年01月22日,核心团队由拥有丰富药物开发经验的*、省级海外归国科学家及资深企业家组成,专注于以创新模式开发新一代抗肿瘤靶向药物。发展模式是基于肿瘤类器官蛋白质组学技术,打造独具特色的药物研发平台,将临床相关组学大数据和AI分析技术应用于各类药物的临床前、临床研究到上市后适应症拓展等各个阶段,从而实现药物的精准高效开发,突破医药研发瓶颈。英诺迈博目前多个自研ADC早期管线,核心管线已进入工艺开发阶段,具备全球首靶首药潜力与百亿市场潜力,是以多组学大数据与AI制药为特色的新一代生物医药研发企业。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

英诺迈博 Financing History (2 rounds)

Manage
天使+
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 融资金额未公开
  • Investor: 蒲公英创投

英诺迈博 Related Industry Tags

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 1,063.8298万(元)
Legal Representative: 毛倩
Date Established:
Credit Code: 91310000MA1H3HFJ8K
Registered Address: 上海市金山区亭林镇松育路181号2幢7936室

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates